{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression/management/new-or-initial-management/","result":{"pageContext":{"chapter":{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management","depth":2,"htmlHeader":"<!-- begin field ae7a8fdc-5d1d-4957-a846-198ea3d4ecf7 --><h2>Scenario: New or initial management</h2><!-- end field ae7a8fdc-5d1d-4957-a846-198ea3d4ecf7 -->","summary":"Covers the initial management of a person with depression.","htmlStringContent":"<!-- begin item dfc76cdb-3598-460b-b8c0-0c1e37ed4534 --><!-- begin field 10b0de18-c54f-4e4b-bd2a-acd900ace252 --><p>From age 18 years onwards.</p><!-- end field 10b0de18-c54f-4e4b-bd2a-acd900ace252 --><!-- end item dfc76cdb-3598-460b-b8c0-0c1e37ed4534 -->","topic":{"id":"5f794dff-eed8-52d6-bb65-1b1a9b1fc50a","topicId":"1b270734-f24e-4b58-8355-adaec350f356","topicName":"Depression","slug":"depression","lastRevised":"Last revised in February 2021","chapters":[{"id":"b34732f5-da05-5558-ac7e-4169aea1302d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bd7d7dbf-c3a1-5690-8d7b-8fe76ab04a16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes"},{"id":"a3c07602-3d45-5287-8c9a-8f9efd7a336a","slug":"update","fullItemName":"Update"}]},{"id":"f87fe236-c4f0-50f8-b694-28b5778f138d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f1acf59a-ed11-5fb0-afc0-cee8532f5512","slug":"goals","fullItemName":"Goals"},{"id":"e98a7293-7a01-5fcc-9e1a-89b044ef1a02","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4182b8a5-9b8d-55e9-a4d9-fad2ca31d873","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c55afa55-15bf-5a19-94a8-21ab0c17f7b7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6e7d7a8-fed0-5900-aab1-c863964e870a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72e01363-0933-5668-b378-6249cb2b64f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d36d2b88-dd20-5f53-882c-81e310273361","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6358ea37-2401-503d-97aa-9d7fa8d3914d","slug":"definition","fullItemName":"Definition"},{"id":"d34c93b9-e882-588a-8711-b0acdcba167b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f8f0d70d-670c-5aae-8508-7f5d3871c3ee","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6b8dc395-d0cf-5820-9d98-cec770054a06","slug":"complications","fullItemName":"Complications"},{"id":"8ed2c15a-e56e-5667-9aa5-18c0957ec394","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"68029dcd-ffd8-58da-b515-711db2fe0564","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d4c125e5-95c8-5ac3-b5fa-10c5c9889c60","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"026c474a-d688-5999-a8bd-67dd4cb231c3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management"},{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management"}]},{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5dce855c-f4fe-577d-8f55-2d88cdf3a9a4","slug":"dose-titration","fullItemName":"Dose and titration"},{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants"},{"id":"6f10b153-e084-5a21-ae48-3acb33411b10","slug":"toxicity-in-overdose","fullItemName":"Toxicity in overdose"},{"id":"0a0e189c-03e7-5c82-ba71-c96545755eeb","slug":"monitoring-antidepressants","fullItemName":"Monitoring antidepressants"},{"id":"f5deab35-56d4-5f9d-bc07-f29103e961ad","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding"},{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs"},{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs"},{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine"},{"id":"3b9d10f7-2760-5bd9-bdf7-92f33416e2c9","slug":"moclobemide","fullItemName":"Moclobemide"},{"id":"823fe65c-0107-5657-8e8f-6ce91ed5cfb6","slug":"reboxetine","fullItemName":"Reboxetine"}]},{"id":"725ab0c0-f1a9-5756-833a-ea5c4f8721bf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"17b06435-7e75-56bf-80c0-57858b6db92c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7eeea9f4-7f32-515a-b661-5f51a513cba7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3907465f-bd0e-530a-b486-c2655ccaba7c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6cef4cda-5622-50b2-9759-9e03266800d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59840e87-e4f4-5c49-a6f1-f67d210f3dc0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d357e2c-3884-5b0c-b9a3-bbf7420da7a9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3a86a38c-4d81-57f0-ac72-7b5260328853","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"944b91f8-0550-5ae2-8f1b-958dbb5e7bb4","slug":"assessment","fullItemName":"Assessment","depth":3,"htmlHeader":"<!-- begin field 86d32472-5bd4-4bea-a570-6e89cd9843ca --><h3>How should I assess someone with depression?</h3><!-- end field 86d32472-5bd4-4bea-a570-6e89cd9843ca -->","summary":null,"htmlStringContent":"<!-- begin item bc62125d-ceb8-4fed-931c-4b411f75dd30 --><!-- begin field 5cc199e5-1cc4-4004-b08a-a70d009a362c --><p><strong>For people with depression, conduct a comprehensive assessment that does not rely simply on a symptom count — take into account both the degree of functional impairment and/or disability associated with the depression and the duration of the episode. </strong></p><ul><li><strong>Assess the <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#assessing-risk-of-suicide\">risk of suicide</a></strong> — ask people directly about suicidal thoughts and intent. </li><li><strong>Consider any factors which may affect the development, course and severity of depression, including: </strong><ul><li>Any history of depression and comorbid mental health or chronic physical disorder.</li><li>Any past history of mood elevation (to determine if the depression may be part of bipolar disorder).</li><li>Any past experience of, and response to, treatments.</li><li>The quality of interpersonal relationships.</li><li>Living conditions and social isolation.</li><li>A family history of mental illness. </li><li>A history of domestic violence or sexual abuse. </li><li>Employment and immigration status. </li><li>Availability of social support. </li></ul></li><li><strong>Be aware of any learning disabilities or acquired cognitive impairments</strong>, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies. </li><li><strong>Identify any safeguarding </strong>concerns for children or vulnerable adults in the care of someone with depression. Follow local safeguarding procedures if appropriate. </li><li><strong>Assess for any c</strong><strong>omorbid conditions associated with depression,</strong> including:<ul><li><strong>Alcohol or substance abuse </strong>— for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>. </li><li><strong>Anxiety </strong>— for more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/diagnosis/diagnosis/\">Detection</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>.</li><li><strong>Eating disorders</strong> — for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eating-disorders/\">Eating disorders</a>.</li><li><strong>Psychotic symptoms </strong>— for more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/psychosis-schizophrenia/\">Psychosis and schizophrenia</a> and <a class=\"topic-reference external-reference\" href=\"/topics/bipolar-disorder/\">Bipolar disorder</a>.</li><li><strong>Dementia </strong>— for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dementia/\">Dementia</a>.</li></ul></li><li><strong>Consider using a validated measure to inform and evaluate treatment</strong>, such as a <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#depression-questionnaires\">depression questionnaire</a>. <ul><li>For people with significant language or communication difficulties, consider using the Distress Thermometer and/or asking a family member or carer about the person's symptoms. <ul><li>The Distress Thermometer is a single-item question screen that identifies distress coming from any source. The person places a mark on the scale answering: 'How distressed have you been during the past week on a scale of 0 to 10?'. Scores of 4 or more indicate a significant level of distress that should be investigated further.</li></ul></li></ul></li></ul><!-- end field 5cc199e5-1cc4-4004-b08a-a70d009a362c --><!-- end item bc62125d-ceb8-4fed-931c-4b411f75dd30 -->","subChapters":[{"id":"5a9240dc-9266-54b1-ab8c-9b33fbfa3bf9","slug":"assessing-risk-of-suicide","fullItemName":"Assessing risk of suicide","depth":4,"htmlHeader":"<!-- begin field 7cb34748-8636-415c-8468-469170325eb4 --><h4>How do I assess the risk of suicide?</h4><!-- end field 7cb34748-8636-415c-8468-469170325eb4 -->","summary":null,"htmlStringContent":"<!-- begin item 36523a8e-a32f-4542-a530-76b137960587 --><!-- begin field dd10dc1d-7a71-499f-816c-8c06e24042b2 --><ul><li><strong>When assessing the risk of suicide, ask the person:</strong><ul><li>Do you have thoughts about death or suicide? </li><li>Do you feel that life is not worth living? </li><li>Have you made a previous suicide attempt? </li><li>Is there a family history of suicide?</li></ul></li><li><strong>If the answer to any of these questions is yes, ask about their plans for suicide:</strong> <ul><li>Have you considered a method?</li><li>Do you have access to the materials?</li><li>Have you made any preparations (for example, written a note)?</li></ul></li><li><strong>Also ask about any protective factors, for example: </strong><ul><li>What keeps you from harming yourself? </li><li>Is there anything that would make life worth living?</li></ul></li><li><strong>Identify risk factors that increase the risk of suicide — these include: </strong><ul><li>Previous suicide attempts or self-harm.</li><li>Active mental illness.</li><li>Family history of mental disorder, suicide or self-harm.</li><li>Male gender.</li><li>Being unemployed.</li><li>Physical health problems.</li><li>Living alone.</li><li>Being unmarried.</li><li>Drug/alcohol dependence.</li><li>Feelings of hopelessness.</li><li>Exposure to suicidal behaviour.</li></ul></li><li><strong>High risk groups include:</strong><ul><li>Young and middle-aged men.</li><li>People in contact with the criminal justice system.</li><li>Specific occupational groups, for example, doctors, nurses, veterinary workers, farmers, agricultural workers.</li></ul></li><li><strong>If there is a risk of self-harm or suicide: </strong><ul><li>Assess whether the person has adequate social support and is aware of sources of help.</li><li>Assess whether there are any dynamic risk factors that can be treated (for example, mental illness, use of alcohol or illicit drugs). </li><li>Arrange help appropriate to the level of risk.</li><li>Advise the person to seek further help if the situation deteriorates.</li></ul></li><li><strong>If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services. </strong></li><li><strong>If the person is considered at low risk, discuss and/or create a safety plan with them, detailing steps they should take if their situation deteriorates. </strong></li></ul><style type=\"text/css\">//<![CDATA[//<![CDATA[//]]>////]]>//</style><!-- end field dd10dc1d-7a71-499f-816c-8c06e24042b2 --><!-- end item 36523a8e-a32f-4542-a530-76b137960587 -->","subChapters":[]},{"id":"cade59bc-c669-543b-af24-1ee551148f64","slug":"depression-questionnaires","fullItemName":"Depression questionnaires","depth":4,"htmlHeader":"<!-- begin field b6a15eb1-4a7c-4aae-a844-a7a7011f9d34 --><h4>Depression questionnaires</h4><!-- end field b6a15eb1-4a7c-4aae-a844-a7a7011f9d34 -->","summary":null,"htmlStringContent":"<!-- begin item 4c7f214d-a252-4e33-bc02-a7a7011f9ab7 --><!-- begin field f4d6c622-dc1f-4fe9-8510-a7a7011f9d34 --><ul><li>Depression questionnaires can be helpful in detecting depression and in assessing severity, but should not be used alone to determine the presence of depression which needs treatment. </li><li>The three recommended questionnaires, which are validated for use in primary care, are PHQ-9 (Patient Health Questionnaire 9), HADS (Hospital Anxiety and Depression Scale), and BDI-II (Beck Depression Inventory-II). <ul><li><strong>PHQ-9</strong><ul><li>A nine-item, self-administered scale, which reflects the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fourth edition) criteria.</li><li>It classifies current symptoms on a scale of 0 (not at all) to 3 (nearly every day) — the maximum score is 27.</li><li>Scores of 5, 10, 15, and 20 represent cut off points for mild, moderate, moderately severe and severe depression, respectively.</li><li>It can be downloaded free of charge from <a href=\"https://www.phqscreeners.com/select-screener\" data-hyperlink-id=\"cd3361d0-a8de-4ac7-a550-aa9900bb023f\">www.phqscreeners.com</a>.</li></ul></li><li><strong>HADS </strong><ul><li>A self-administered scale, with 14 questions in total (seven covering depression and seven covering anxiety).</li><li>The maximum score for each subscale is 21.</li><li>Scores of 8-10, 11-14, and 15-21 represent cut off points for mild, moderate and severe depression respectively. </li><li>A paper version is available to purchase from <a href=\"https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/\" data-hyperlink-id=\"4e341924-6088-4ea9-850b-ab1901010c51\">https://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-hads/</a> as an online version is no longer available.</li></ul></li><li><strong>BDI-II</strong><ul><li>A 21-item, self-administered scale that uses DSM-5 criteria.</li><li>Each question is rated from 0 to 3 — the maximum score is 63.</li><li>Scores of 14-19, 20-28, and 29-63 can be interpreted as mild, moderate, and severe depression respectively.  </li><li>It is available to purchase from <a href=\"http://www.pearsonassessments.com/\" data-hyperlink-id=\"8ca9387a-d783-4ef0-8da2-a9910049e7bc\">www.pearsonassessments.com</a>.</li></ul></li></ul></li></ul><!-- end field f4d6c622-dc1f-4fe9-8510-a7a7011f9d34 --><!-- end item 4c7f214d-a252-4e33-bc02-a7a7011f9ab7 -->","subChapters":[]},{"id":"ff92a018-1045-53f0-ad12-c076a21e11e8","slug":"basis-for-recommendation-bf6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 21230a80-e94f-4fc8-81dd-a70700fef509 --><h4>Basis for recommendation</h4><!-- end field 21230a80-e94f-4fc8-81dd-a70700fef509 -->","summary":null,"htmlStringContent":"<!-- begin item bf65bf1b-acd3-4164-8662-a70700fef409 --><!-- begin field c841d86b-03bb-4894-aa22-a70700fef509 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>], <em>Common mental health disorders: identification and pathways to care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2011</a>], a Canadian guideline from the British Columbia Medical Association (BCMA) <em>Major depressive disorder in adults: diagnosis & management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">BCMA, 2013</a>], expert opinion in narrative reviews <em>Exploring thoughts of suicide</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Sinclair, 2017</a>], and <em>Can we usefully stratify patients according to suicide risk?</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Large, 2017</a>], a US guideline from the Institute for Clinical Systems Improvement (ICSI) <em>Depression in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ICSI, 2016</a>], and the HM Government document <em>Preventing suicide in England: Fourth progress report of the cross-government outcomes strategy to save lives </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">HM Government, 2019</a>].  </p><h5>Assessing the risk of suicide</h5><ul><li>The recommendation to ask people with depression directly about suicidal ideation and intent is based on the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]. </li><li>However, a review of seven meta-analyses of studies among psychiatric patients or people presenting with self harm [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Large, 2017</a>] found that there are not any individual clinical risk factors, including suicidal thoughts and behaviours, that are sufficiently accurate to be useful as the basis to allocate interventions.<ul><li>No high risk determination, whether based on a model that integrated multiple risk factors or a suicide risk scale, was strongly associated with later death by suicide. Moreover, almost half of all people who die by suicide come from lower risk strata, indicating a low sensitivity in high risk status.</li><li>The overwhelming majority of people who might be viewed as at high risk of suicide will not die by suicide. </li></ul></li><li>A meta-analysis that looked at risk factors for self harm as well as suicide found only four risk factors with strong evidence to support them [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Chan, 2016</a>]:  <ul><li>Previous episodes of self harm.</li><li>Male gender.</li><li>Being unemployed.</li><li>Having physical health problems.</li></ul></li><li>The UK National Confidential Inquiry into suicides identified four additional risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">University of Manchester, 2018</a>]: <ul><li>Living alone.</li><li>Being unmarried.</li><li>Drug/alcohol dependence.</li><li>Active mental illness.</li></ul></li><li>The HM Government document <em>Preventing suicide in England: Fourth progress report of the cross-government outcomes strategy to save lives</em>, identified the following high-risk groups [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">HM Government, 2019</a>]:  <ul><li>Young and middle-aged men.</li><li>People in the care of mental health services, including inpatients.</li><li>People in contact with the criminal justice system.</li><li>Specific occupational groups, such as doctors, nurses, veterinary workers, farmers and agricultural workers.</li><li>People with a history of self-harm.</li></ul></li></ul><p><strong>Consider comorbid medical conditions </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]</p><ul><li>The recommendation to consider a history of depression and comorbid mental health or physical disorders is based on the NICE guideline which states that suicide is commonest in those with comorbid physical and mental illness. <style type=\"text/css\">//<![CDATA[//]]>//</style></li></ul><!-- end field c841d86b-03bb-4894-aa22-a70700fef509 --><!-- end item bf65bf1b-acd3-4164-8662-a70700fef409 -->","subChapters":[]}]},{"id":"920b5724-1721-50b3-b431-a2e770e319fe","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 63d3e7a6-f1f5-40f6-aa57-a70700ff0c01 --><h3>How should I manage depression in primary care?</h3><!-- end field 63d3e7a6-f1f5-40f6-aa57-a70700ff0c01 -->","summary":null,"htmlStringContent":"<!-- begin item e7084a5c-934b-4100-9c89-a70700ff0b0d --><!-- begin field 93ce43ba-2555-4e1a-88eb-a70700ff0c01 --><ul><li><strong>Manage suicide risk.</strong> Options include:<ul><li>Contacting the Crisis Resolution and Home Treatment <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#crisis-services\">(CRHT)</a> team for an urgent assessment.<ul><li>Voluntary admission or <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#compulsory-admission\">compulsory admission</a> may be required.</li></ul></li><li>Reviewing a person frequently in primary care. </li></ul></li><li><strong>Manage any safeguarding concerns</strong> for children or vulnerable adults in their care. Follow local safeguarding procedures if appropriate. </li><li><strong>Manage any comorbid condition associated with depression</strong>, such as: <ul><li><strong>Alcohol or substance abuse</strong> — treat the underlying drinking or substance problem; depressive symptoms frequently resolve following this. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>.</li><li><strong>Anxiety</strong> — where depression is accompanied by anxiety, the first priority should usually be to treat the depression. For information on treating people with anxiety see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>.</li><li><strong>Psychotic symptoms</strong> — seek expert advice. The use of antidepressants in people with bipolar disorder can trigger hypomania/mania. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/psychosis-schizophrenia/\">Psychosis and schizophrenia</a> and <a class=\"topic-reference external-reference\" href=\"/topics/bipolar-disorder/\">Bipolar disorder standard</a>.</li><li><strong>Eating disorders</strong> — seek expert advice. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eating-disorders/\">Eating disorders</a>.</li><li><strong>Dementia </strong>— for people with mild to moderate dementia who have mild to moderate depression, consider psychological treatments, but do not routinely offer antidepressants to manage mild to moderate depression in people with mild to moderate dementia. Unless they are indicated for a pre-existing severe mental health problem, treat the underlying depression. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dementia/\">Dementia</a>. </li></ul></li><li><strong>For people with mild depression who do not want an intervention, or people with subthreshold depressive symptoms who request an intervention, consider a period of active monitoring, and:</strong> <ul><li>Discuss the presenting problems and any concerns they may have. </li><li>Provide information about the nature and course of depression.</li><li>Arrange <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#follow-up\">follow up</a>, normally within 2 weeks (consider contacting the person if they do not attend follow-up appointments).</li></ul></li><li><strong>For people with persistent subthreshold depressive symptoms or mild-to-moderate depression:</strong><ul><li>Consider offering a <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#psychosocial-psychological-interventions\">low-intensity psychosocial intervention</a> — this is accessed by referral or self-referral to IAPT (Improving Access to Psychological Therapies).  </li><li>Consider group-based CBT for people who decline low intensity psychosocial interventions. </li><li>Avoid the routine use of <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#choosing-an-antidepressant\">antidepressants</a>, but consider this for people with: <ul><li>A history of moderate or severe depression.</li><li>Subthreshold depressive symptoms that have persisted for a long period (typically at least 2 years). </li><li>Subthreshold symptoms or mild depression that persists after other interventions.</li><li>Mild depression that is complicating the care of a chronic physical health problem. </li></ul></li></ul></li><li><strong>For people with moderate or severe depression</strong> — offer an antidepressant and a <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#psychosocial-psychological-interventions\">high-intensity psychological intervention</a>. Psychological interventions are accessed by referral or self-referral to IAPT. The type of intervention offered will depend on the severity of depression, the response to any previous treatment, the likelihood of adherence to treatment and potential adverse effects, and the person's preferences and priorities.  </li><li><strong>For people starting an antidepressant:</strong><ul><li>Consider suicide risk and toxicity in overdose. </li><li>Explain that symptoms of anxiety may initially worsen. </li><li>Explain that antidepressants take time to work. </li><li>Explain that antidepressants should be continued for at least 6 months following remission of symptoms, as this greatly reduces the risk of relapse. </li></ul></li><li><strong>For people having difficulty sleeping, </strong>offer sleep hygiene advice. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/management/managing-short-term-insomnia-less-3-months/#good-sleep-hygiene\">Good sleep hygiene</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/\">Insomnia</a>. </li><li><strong>Arrange <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#follow-up\">follow up</a></strong> to assess the response to treatment, the need for further management, and for any adverse effects or compliance issues associated with anti-depressants.</li><li><strong>Provide <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#information-advice\">information and advice</a> </strong>about depression and its treatment.</li><li><strong>Manage people with </strong><strong>seasonal</strong><strong> affective disorder</strong> the same way as other people with depression. </li></ul><!-- end field 93ce43ba-2555-4e1a-88eb-a70700ff0c01 --><!-- end item e7084a5c-934b-4100-9c89-a70700ff0b0d -->","subChapters":[{"id":"b39a72b3-f18a-5833-9b45-e7469fd7c03e","slug":"crisis-services","fullItemName":"Crisis services","depth":4,"htmlHeader":"<!-- begin field 47cb4312-6673-46b2-a627-a7a7011b8bc3 --><h4>Crisis services</h4><!-- end field 47cb4312-6673-46b2-a627-a7a7011b8bc3 -->","summary":null,"htmlStringContent":"<!-- begin item 48bfe117-17b6-4c9b-be14-a7a7011b8986 --><!-- begin field f3f1ccf3-dbb8-4049-a69c-a7a7011b8bc3 --><ul><li>Crisis resolution and home treatment (CRHT) teams usually include a psychiatrist, mental health nurses, social workers and support workers and are available 24 hours a day, 7 days a week. </li><li>The CRHT team assesses the person's needs, manages the risks of being at home, assists with self-help strategies, visits frequently, offers psychological and practical help, and administers medication. </li><li>While there is insufficient evidence to clearly support their use in depression, the National Institute for Health and Clinical Excellence (NICE) advises that crisis teams may have a role for a small number of people with depression who require more intensive care. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Mind, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>] </p><!-- end field f3f1ccf3-dbb8-4049-a69c-a7a7011b8bc3 --><!-- end item 48bfe117-17b6-4c9b-be14-a7a7011b8986 -->","subChapters":[]},{"id":"88a69241-98f5-5b9a-b4df-c159f9cbf99e","slug":"compulsory-admission","fullItemName":"Compulsory admission","depth":4,"htmlHeader":"<!-- begin field ebc0cf77-7016-42ee-836b-a7a700f257f4 --><h4>Compulsory admission</h4><!-- end field ebc0cf77-7016-42ee-836b-a7a700f257f4 -->","summary":null,"htmlStringContent":"<!-- begin item 4848c80d-0df7-4764-8183-a7a700f255ac --><!-- begin field e09f9d7a-583a-4396-b2db-a7a700f257f4 --><ul><li><strong>If the person needs to be admitted to </strong><strong>hospital</strong><strong>,</strong> every attempt should be made to persuade them to go voluntarily.</li><li><strong>If admission is necessary but the person declines,</strong> compulsory admission may be arranged under sections 2, 3, or 4 of the Mental Health Act.</li><li><strong>The Mental Health Act allows compulsory admission</strong> of people who: <ul><li>Have a mental disorder of a nature or degree that warrants assessment or treatment in hospital, and</li><li>Need to be admitted in the interests of their own health or safety, or for the protection of other people.</li></ul></li><li><strong>Compulsory admission is arranged using the appropriate section of the Mental Health Act.</strong><ul><li><strong>Section 2 allows compulsory admission for up to 28 days for assessment.</strong></li><li><strong>Section 3 allows compulsory admission for up to 6 months for treatment. </strong><ul><li>Sections 2 and 3 require an application from an approved mental health professional, or the person's nearest relative, and written recommendations from two doctors; one of whom is section 12 approved (usually a psychiatrist) and one who has previous acquaintance with the individual (usually the person's GP if at all practicable). </li><li>For admission under section 2, where there is no obvious person to provide the second medical recommendation (for example because the person is not registered with a GP or is not known to local mental health services), another section 12-approved doctor is usually asked to assess the individual. However, in cases where this is not practicable, any registered medical practitioner may provide the second recommendation as long as there are no potential conflicts of interest (for example, they work in the same hospital as the doctor providing the first recommendation). </li><li>The person can be examined jointly or separately by the two doctors.</li></ul></li><li><strong>Section 4 is used in exceptional cases to permit compulsory admission for up to 72 hours</strong> if there is urgent necessity, and undesirable delay would occur while trying to arrange admission under normal procedures. <ul><li>It requires an application from an AMHP (or the person's nearest relative) and just one medical recommendation, preferably from a doctor with previous acquaintance (usually the GP).</li><li>Where the person has been compulsorily admitted under an emergency section 4, this section is usually converted to a section 2 (usually requiring further involvement of the GP).</li></ul></li><li><strong>Section 136 may be used by police to take people from a public place to a place of safety</strong> <strong>so they can be assessed. </strong></li></ul></li><li>Young people aged 16 or 17 years who have capacity to consent, but refuse to do so, cannot be admitted or kept in hospital for treatment for a mental disorder on the basis of their parents' consent — they will need to be formally detained under the Mental Health Act. </li><li>Guidance and forms for the most common sections of the Mental Health Act can be accessed from the <a data-hyperlink-id=\"162b1626-4056-41a6-8f45-a9910049e5e2\" href=\"https://www.gov.uk/government/organisations/department-of-health\">Department of Health website</a>, and a <a data-hyperlink-id=\"c45945cc-f119-443e-96a6-ab200100c968\" href=\"https://www.gov.uk/government/publications/mental-health-act-1983-reference-guide\">reference guide to the Mental Health Act 1993</a> is also available.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">DH, 2015</a>]</p><!-- end field e09f9d7a-583a-4396-b2db-a7a700f257f4 --><!-- end item 4848c80d-0df7-4764-8183-a7a700f255ac -->","subChapters":[]},{"id":"1d0c6e69-ad0f-57f0-a6ab-f8983e986d2b","slug":"psychosocial-psychological-interventions","fullItemName":"Psychosocial and psychological interventions","depth":4,"htmlHeader":"<!-- begin field 7b0ac4fa-3120-4d12-afc8-a7a7012369ae --><h4>Psychosocial and psychological interventions</h4><!-- end field 7b0ac4fa-3120-4d12-afc8-a7a7012369ae -->","summary":null,"htmlStringContent":"<!-- begin item 73f7cd0f-4736-4cb6-be8b-a7a701236786 --><!-- begin field 766e7115-f46b-402d-996b-a7a7012369ae --><ul><li><strong>Low-intensity psychosocial interventions</strong> are suitable for people with persistent subthreshold depressive symptoms or mild depression, and include:<ul><li>Individual guided self-help, based on the principles of cognitive behavioural therapy (CBT) — this includes written material or other media relevant to reading age, and usually consists of 6–8 sessions (face-to-face and via telephone) over 9–12 weeks.</li><li>Computerized cognitive behavioural therapy (CCBT) — this can be provided via a stand-alone computer-based or web-based programme and usually takes place over 9–12 weeks. </li><li>Structured group-based physical activity programme — usually consists of 3 sessions per week of moderate duration (45 minutes to 1 hour) over 10–14 weeks.</li></ul></li><li><strong>Group-based CBT </strong>is suitable for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions — usually consists of 10–12 meetings of 8–10 participants over 12–16 weeks.</li><li><strong>High-intensity psychological interventions</strong> are generally reserved for people with moderate-to-severe depression, and include:<ul><li>Individual CBT — usually given over 16–20 sessions over 3–4 months. For people with severe depression, two sessions per week might be provided for the first 2–3 weeks of treatment. </li><li>Interpersonal therapy — duration and number of sessions is similar to CBT. </li><li>Behavioural activation — duration and number of sessions is similar to CBT. </li><li>Couples therapy — usually consists of 15–20 sessions over 5–6 months. </li></ul></li><li><strong>Counselling and short-term psychodynamic therapy</strong> — these can be considered for people who decline antidepressants and high-intensity psychological interventions.<ul><li>Counselling is usually provided in 6–10 sessions over a period of 8–12 weeks. </li><li>Short-term psychodynamic therapy usually consists of 16–20 sessions over 4–6 months.</li><li>Discuss with the person the uncertainty of the effectiveness of these options.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]</p><!-- end field 766e7115-f46b-402d-996b-a7a7012369ae --><!-- end item 73f7cd0f-4736-4cb6-be8b-a7a701236786 -->","subChapters":[]},{"id":"31b17cbe-5e2a-56b1-ad1c-01e5a15c5ca3","slug":"basis-for-recommendation-13c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 504d0cc0-21e1-473e-a9ec-a70700ff0c06 --><h4>Basis for recommendation</h4><!-- end field 504d0cc0-21e1-473e-a9ec-a70700ff0c06 -->","summary":null,"htmlStringContent":"<!-- begin item 13c19bb1-70c8-4386-aa6f-a70700ff0c06 --><!-- begin field 5dfc7cee-07bd-4f0b-a4ec-a70700ff0c06 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>], <em>Common mental health disorders: identification and pathways to care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2011</a>], <em>Depression in adults with a chronic physical health problem </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2009</a>], <em>Eating disorders: recognition and treatment </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">NICE, 2017</a>], and <em>Dementia: assessment, management and support for people living with dementia and their carers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">NICE, 2018</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>The management of harmful drinking and alcohol dependence in primary care</em>  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SIGN, 2003</a>], the Department of Health (DH) <em>Reference guide for the Mental Health Act 1993</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">DH, 2015</a>], the University of Oxford's Centre for Suicide Research (CSR) guideline <em>Assessment of suicide risk in people with depression</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">CSR, 2013</a>], and what CKS consider good clinical practice.</p><!-- end field 5dfc7cee-07bd-4f0b-a4ec-a70700ff0c06 --><!-- end item 13c19bb1-70c8-4386-aa6f-a70700ff0c06 -->","subChapters":[]}]},{"id":"cba41e14-b4a8-5aa7-9ff5-e961646ca151","slug":"choosing-an-antidepressant","fullItemName":"Choosing an antidepressant","depth":3,"htmlHeader":"<!-- begin field e01f3584-7c8a-4bf7-844c-a70700ff4503 --><h3>Which antidepressant should I prescribe?</h3><!-- end field e01f3584-7c8a-4bf7-844c-a70700ff4503 -->","summary":null,"htmlStringContent":"<!-- begin item 56260e13-4869-462c-abea-a70700ff4412 --><!-- begin field 3fb91554-0160-4eef-8d6b-a70700ff4503 --><ul><li><strong>When choosing an antidepressant, take into consideration: </strong><ul><li>The person's preference.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/depression/prescribing-information/toxicity-in-overdose/\">Toxicity in overdose</a>  — avoid tricyclic antidepressants or venlafaxine if there is a history, or likelihood, of overdose.</li><li>The adverse effect profile — for example, sedation, sexual adverse effects, weight gain.</li><li>Any associated psychiatric disorder or concurrent medical illness or condition.</li><li>Current drug treatments that may interact with antidepressant drugs, including any over the counter medication, herbal remedies or illegal drugs. </li><li>For more information, see the sections on contraindications and cautions, adverse effects and drug interactions in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/depression/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>Although the above factors may influence the choice of antidepressant, in general: </strong><ul><li><strong>If this is </strong><strong>a first</strong><strong> episode of depression</strong>, consider:<ul><li>Prescribing a generic selective serotonin reuptake inhibitor (SSRI), such as citalopram, fluoxetine, paroxetine, or sertraline. </li></ul></li><li><strong>If this is a recurrent episode of depression, consider: </strong><ul><li>Prescribing an antidepressant that the person has had a good response to previously. </li><li>Avoiding antidepressants that the person has previously failed to respond to or could not tolerate.</li></ul></li><li>If the person has a chronic physical health problem: <ul><li>Sertraline may be preferred, because it has a lower risk of drug interactions.</li><li>If an SSRI is prescribed, consider gastroprotection in older people who are taking nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin. </li></ul></li></ul></li><li>For information regarding the use of antidepressants in women who are pregnant or breastfeeding, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression-antenatal-postnatal/\">Depression - antenatal and postnatal</a>.</li></ul><style type=\"text/css\">//<![CDATA[//<![CDATA[//]]>////]]>//</style><!-- end field 3fb91554-0160-4eef-8d6b-a70700ff4503 --><!-- end item 56260e13-4869-462c-abea-a70700ff4412 -->","subChapters":[{"id":"1bd3c83c-c3c8-51c4-bd86-fcaa0f0097cf","slug":"basis-for-recommendation-0c3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 79660bfc-c345-402a-8536-a70700ff4508 --><h4>Basis for recommendation</h4><!-- end field 79660bfc-c345-402a-8536-a70700ff4508 -->","summary":null,"htmlStringContent":"<!-- begin item 0c3da2d7-f100-48e1-882a-a70700ff4508 --><!-- begin field 1016fc01-091a-4ea0-b5f7-a70700ff4508 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>], <em>Depression in adults with a chronic physical health problem </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2009</a>], the British Association for Psychopharmacology<em> Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Cleare, 2015</a>], and the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">MHRA, 2016</a>]. </p><p><strong>Choice of antidepressant </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]</p><ul><li>NICE concluded that the efficacy of the different antidepressants is largely equivalent.<ul><li>It found no evidence that newer antidepressants such as escitalopram, duloxetine, or venlafaxine are more effective than other antidepressants — the choice of antidepressant should depend on adverse effect profiles, the person's preference, previous experience of treatments, likelihood to cause discontinuation symptoms, and safety in overdose.</li><li>A generic selective serotonin reuptake inhibitor (SSRI) is preferred as they have a better adverse effect profile than other antidepressants and are less toxic in overdose.</li></ul></li><li>NICE recommends that citalopram and sertraline may be preferred in people with a chronic physical health problem because they have a lower propensity for drug interactions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2009</a>].</li><li>However CKS recommends sertraline as the preferred antidepressant for people with a chronic physical health problem.<ul><li>Citalopram and escitalopram have been found to prolong the QT interval and should be avoided in people with congenital long QT interval or who have pre-existing QT interval prolongation, or in people who are already taking medication known to prolong the QT interval as there may be an additive effect [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">MHRA, 2014a</a>].  </li></ul></li><li>A recent systematic review and network meta-analysis of 522 double-blind parallel randomized controlled trials (n = 116,477) which compared the effectiveness and acceptability of 21 antidepressants against each other or placebo in people with moderate to severe depression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Cipriani, 2018</a>] found that escitalopram, mirtazapine, paroxetine, agomelatine, and sertraline had a relatively higher response and lower dropout rate than the other antidepressants. By contrast, reboxetine, trazodone, and fluvoxamine were associated with generally inferior efficacy and acceptability profiles compared with the other antidepressants.<ul><li>However, in head to head studies when all data were considered, overall it found few differences between antidepressants, and there was more diversity in the range of efficacy and dropout patterns seen across the head-to-head comparisons than the meta-analysis of antidepressants versus placebo.</li></ul></li></ul><style type=\"text/css\">//<![CDATA[//<![CDATA[//]]>////]]>//</style><!-- end field 1016fc01-091a-4ea0-b5f7-a70700ff4508 --><!-- end item 0c3da2d7-f100-48e1-882a-a70700ff4508 -->","subChapters":[]}]},{"id":"ee6d9f38-9b86-554f-9c7e-f705b628fa53","slug":"chronic-physical-health-problems","fullItemName":"Chronic physical health problems","depth":3,"htmlHeader":"<!-- begin field 499d9bf4-1c62-446b-a04f-ab2501111e9b --><h3>Which antidepressants are recommended for people with chronic physical health problems?</h3><!-- end field 499d9bf4-1c62-446b-a04f-ab2501111e9b -->","summary":null,"htmlStringContent":"<!-- begin item f87508b4-8985-4c1c-a7f6-ab2501111e31 --><!-- begin field 2e2d64b7-f8d1-443a-96de-ab2501111e9b --><ul><li>Prescribe a generic selective serotonin reuptake inhibitor (SSRI), such as sertraline or citalopram unless these are contraindicated or there is a significant drug interaction. <ul><li>Do not use citalopram or escitalopram in people who are taking medication that could prolong the QT interval. </li></ul></li><li>For a brief summary on which antidepressants may be prescribed for people with chronic physical health problems, see Table 1. For more detailed information see appendix 16 of the full <a href=\"https://www.nice.org.uk/guidance/CG91\" data-hyperlink-id=\"a34f7975-6a05-4ac4-8e2c-a98f0161c2f4\">NICE guideline</a>.</li></ul><p><strong>Table 1. </strong>Antidepressants recommended for people with a chronic physical health problem.</p><table data-table-id=\"4eea3f51-4154-4e98-8316-acce014f8f06\"><thead><tr><th scope=\"col\">Medication being taken for a chronic physical health problem</th><th scope=\"col\">Antidepressants that should not normally be offered</th><th scope=\"col\">Suitable options </th></tr></thead><tbody><tr><td>Nonsteroidal anti-inflammatory drugs (NSAIDs)</td><td>Selective serotonin reuptake inhibitor (SSRI) or a serotonin noradrenaline reuptake inhibitor (SNRI) (if no suitable alternative can be found, offer gastroprotection) </td><td>Mirtazapine, moclobemide, reboxetine, or trazodone</td></tr><tr><td>Warfarin</td><td>Tricyclic antidepressants (TCAs), SSRIs, or SNRIs</td><td>*Mirtazapine, reboxetine, trazodone, or mianserin</td></tr><tr><td>Heparin</td><td>SSRI or an SNRI</td><td>Any alternative (for example mirtazapine, trazodone, reboxetine, or a TCA).</td></tr><tr><td>Aspirin</td><td>SSRIs and SNRIs (if no suitable alternative can be found, offer gastroprotection) </td><td><p>Mirtazapine.</p><p>When aspirin is used alone, consider trazadone or reboxetine. </p></td></tr><tr><td>Anti-epileptic drugs </td><td>All antidepressants lower the seizure threshold — seek specialist advice. Consider whether depression may be worsened by the anti-epileptic drug. </td><td><p>SSRIs: sertraline (preferred option)</p><p>Fluoxetine and fluvoxamine (not best options due to increased risk of drug interactions)</p><p>Moclobemide (second choice after SSRIs)</p><p>TCAs – use cautiously (doxepin may have lowest risk of seizures)</p></td></tr><tr><td>Triptan drugs for migraine</td><td>Do not offer SSRIs. </td><td>Mirtazapine, trazadone, mianserin, or reboxetine.</td></tr><tr><td>MAO-B inhibitors (such as selegiline and rasagiline)</td><td>SSRIs. </td><td>Mirtazapine, trazadone, mianserin, or reboxetine.</td></tr><tr><td>Clozapine, methadone, tizanidine</td><td><p>Fluvoxamine. </p><p>Do not offer citalopram or escitalopram</p></td><td>Sertraline </td></tr><tr><td>Theophylline</td><td>Fluvoxamine. </td><td><br>Sertraline or citalopram</td></tr><tr><td>Flecainide or propafenone</td><td>Do not offer citalopram or escitalopram</td><td><p>Sertraline (preferred option)</p><p>Mirtazapine or moclobemide may also be used</p></td></tr><tr><td>Atomoxetine</td><td>Do not offer fluoxetine, paroxetine, citalopram, or escitalopram</td><td>A different SSRI.</td></tr><tr><td colspan=\"3\"><p><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">MHRA, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>]  * INR may increase slightly. </p></td></tr></tbody></table><!-- end field 2e2d64b7-f8d1-443a-96de-ab2501111e9b --><!-- end item f87508b4-8985-4c1c-a7f6-ab2501111e31 -->","subChapters":[{"id":"0198a5fd-c9d3-51ea-a5bb-0c17d62af0f2","slug":"basis-for-recommendation-f4c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4de6680d-4a7c-4eaa-8f0f-ab2501111ea2 --><h4>Basis for recommendation</h4><!-- end field 4de6680d-4a7c-4eaa-8f0f-ab2501111ea2 -->","summary":null,"htmlStringContent":"<!-- begin item f4cb7728-fcda-4ce9-9431-ab2501111ea1 --><!-- begin field 6ec53523-31a1-4617-88d0-ab2501111ea2 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Depression in adults with a chronic physical health problem</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2009</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Citalopram and escitalopram: QT interval prolongation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">MHRA, 2014a</a>], the Specialist Pharmacy Service (SPS) document <em>What is the most appropriate antidepressant to use in people with epilepsy?</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019a</a>] and the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>].</p><!-- end field 6ec53523-31a1-4617-88d0-ab2501111ea2 --><!-- end item f4cb7728-fcda-4ce9-9431-ab2501111ea1 -->","subChapters":[]}]},{"id":"c69c0d37-31e0-5528-b502-5fa12f19794d","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field be6f96fe-a0cb-4260-9fda-a70700ff5948 --><h3>What information and advice should I provide about depression?</h3><!-- end field be6f96fe-a0cb-4260-9fda-a70700ff5948 -->","summary":null,"htmlStringContent":"<!-- begin item 73afab8f-b298-425a-8bd1-a70700ff57bc --><!-- begin field 83efccd8-5aa3-4a80-ae9c-a70700ff5948 --><ul><li><strong>Give advice about guided self-help groups, support groups and other local and national resources.</strong> <strong>Guided self-help may include:</strong><ul><li>Self-help leaflets or books, using cognitive behavioural therapy principles.</li><li>Self-help computer programmes or the internet.</li><li>Exercise sessions (three each week for up to 1 hour), for 10–12 weeks.</li></ul></li><li><strong>Organizations</strong><strong> that offer materials and/or support to people with depression include:</strong><ul><li>MIND — <a data-hyperlink-id=\"b5fdf9ba-706c-45de-a31e-a98f015daf85\" href=\"http://www.mind.org.uk/\">www.mind.org.uk</a>.</li><li>Depression Alliance — <a data-hyperlink-id=\"3b9aab09-b301-4cf0-b131-a98f015dafbb\" href=\"http://www.depressionalliance.org/\">www.depressionalliance.org</a>.</li><li>Depression UK — <a data-hyperlink-id=\"954d4cd2-1fb1-4cd5-9ce2-a98f015db088\" href=\"http://www.depressionuk.org/\">www.depressionuk.org</a>.</li><li>Mental Health Foundation — <a data-hyperlink-id=\"0ea01d87-7105-4d6b-9662-a98f015db535\" href=\"http://www.mentalhealth.org.uk/\">www.mentalhealth.org.uk</a>.</li><li>Samaritans — telephone helpline: 08457 90 90 90.</li><li>SaneLine: telephone helpline: 0845 767 8000. Open from 6pm to 11pm every day of the year.</li></ul></li><li><strong>Provide written and verbal information about depression and its treatment. Good quality patient information can be found on the website of the Royal College of Psychiatrists (<a data-hyperlink-id=\"d2f20758-8c7e-4cd5-b84a-a98f015db561\" href=\"http://www.rcpsych.ac.uk/\">www.rcpsych.ac.uk</a>).</strong><ul><li>Leaflets include, <a data-hyperlink-id=\"93a0b09c-5777-4141-abf9-a98f015db62e\" href=\"http://www.rcpsych.ac.uk/expertadvice/problemsdisorders/depression.aspx\">Depression</a>, <a data-hyperlink-id=\"7b0db4bf-4512-4b06-b39d-a98f015db7db\" href=\"http://www.rcpsych.ac.uk/expertadvice/problemsdisorders/depressionkeyfacts.aspx\">Depression: key facts</a>, <a data-hyperlink-id=\"a53046f3-44b2-4a58-85a8-a98f015db974\" href=\"http://www.rcpsych.ac.uk/expertadvice/problemsdisorders/depressioninolderadults.aspx\">Depression in Older Adults</a>, <a data-hyperlink-id=\"870efb20-bc50-4a9f-8b4d-a98f015dbb06\" href=\"http://www.rcpsych.ac.uk/expertadvice/problemsdisorders/depressionmenkeyfacts.aspx\">Depression and Men: key facts</a>, <a data-hyperlink-id=\"ccc0fbc7-f60d-4968-9857-a98f015dbc97\" href=\"http://www.rcpsych.ac.uk/expertadvice/treatmentswellbeing/antidepressants.aspx\">Antidepressants</a>, and <a data-hyperlink-id=\"b2c90b34-fb5e-49fe-bf8b-a98f015dbcb5\" href=\"http://www.rcpsych.ac.uk/expertadvice/treatmentswellbeing/cbt.aspx\">Cognitive Behavioural Therapy</a>.</li></ul></li><li><strong>Advise the person receiving treatment:</strong><ul><li>To be vigilant for worsening depressive symptoms and suicidal ideas, particularly when starting and changing medications, and at times of increased personal stress. Advise them to seek help promptly if they are concerned. </li><li>That it usually takes 2–4 weeks for symptoms to improve. </li><li>That antidepressants should be taken for at least 6 months after they have recovered, to reduce the risk of relapse. People who are at high risk of relapse may need to take them for longer than this. </li><li>That antidepressant drugs are not addictive – however, inform them that discontinuation symptoms are experienced in a third of people who stop treatment. </li><li>That if they stop taking antidepressants abruptly, miss doses, or do not take the full dose, they may experience discontinuation symptoms. These can include restlessness, problems sleeping, unsteadiness, sweating, abdominal symptoms, altered sensations (for example electric shock sensations in the head), or altered feelings (irritability, anxiety, confusion).<ul><li>Explain that whilst the withdrawal symptoms which arise when stopping or reducing antidepressants can be mild and self-limiting, there is substantial variation in people's experience, with symptoms lasting much longer (sometimes months or more) and being more severe for some patients.</li></ul></li><li>That some antidepressants potentially have sedating effects, and may affect the person's ability to drive. This effect is likely to be greatest in the first month after starting treatment or after increasing the dose. The Driver and Vehicle Licensing Agency (DVLA) advises that people should not drive during this time if affected.</li><li>Not to use St John's wort.</li></ul></li></ul><!-- end field 83efccd8-5aa3-4a80-ae9c-a70700ff5948 --><!-- end item 73afab8f-b298-425a-8bd1-a70700ff57bc -->","subChapters":[{"id":"40c2fee4-0479-5d57-ae76-4a6ddf7c5a10","slug":"basis-for-recommendation-490","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 87ae2e72-a347-4212-b959-a70700ff594c --><h4>Basis for recommendation</h4><!-- end field 87ae2e72-a347-4212-b959-a70700ff594c -->","summary":null,"htmlStringContent":"<!-- begin item 49049471-d436-4d29-978a-a70700ff594c --><!-- begin field f00509d6-d34b-4c7e-9c07-a70700ff594c --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>], the British Association for Psychopharmacology<em> Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Cleare, 2015</a>], and the Driver and Vehicle Licensing Agency (DVLA) guide <em>Assessing fitness to drive – a guide for medical professionals</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">DVLA, 2019</a>]. </p><!-- end field f00509d6-d34b-4c7e-9c07-a70700ff594c --><!-- end item 49049471-d436-4d29-978a-a70700ff594c -->","subChapters":[]}]},{"id":"a7cba948-cf8a-5780-967b-2afc61dad21d","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field d3f65fb7-bc0e-4a1e-95fc-a70700ff22c1 --><h3>When should I review someone with depression?</h3><!-- end field d3f65fb7-bc0e-4a1e-95fc-a70700ff22c1 -->","summary":null,"htmlStringContent":"<!-- begin item 007a0c6a-1a31-4b69-9a32-a70700ff20db --><!-- begin field a3a18443-9ce4-4a0c-bdc2-a70700ff22c1 --><ul><li><strong>The review period should be determined by the risk of suicide and the need to assess the tolerability and effectiveness of any treatments started or changed.</strong></li><li><strong>F</strong><strong><strong>or </strong>people not considered to be at an increased risk of suicide: </strong><ul><li>Arrange an initial review within 2 weeks.</li><li>Review regularly thereafter — for example, every 2–4 weeks for the first 3 months and if the response to treatment is good, longer review intervals can be considered.</li></ul></li><li><strong>For people at an increased risk of suicide, or people aged under 30 years: </strong><ul><li>Arrange an initial review within 1 week.  </li><li>Review frequently thereafter until the risk is no longer considered clinically important.</li></ul></li></ul><!-- end field a3a18443-9ce4-4a0c-bdc2-a70700ff22c1 --><!-- end item 007a0c6a-1a31-4b69-9a32-a70700ff20db -->","subChapters":[{"id":"2a7f8cca-cd6c-51bf-b616-fc9cc48bed29","slug":"basis-for-recommendation-c8e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d33efdda-b434-402e-93cd-a70700ff22c5 --><h4>Basis for recommendation</h4><!-- end field d33efdda-b434-402e-93cd-a70700ff22c5 -->","summary":null,"htmlStringContent":"<!-- begin item c8ee52fb-239a-45f4-a905-a70700ff22c5 --><!-- begin field 6209faa0-c433-4b02-b978-a70700ff22c5 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>].</p><!-- end field 6209faa0-c433-4b02-b978-a70700ff22c5 --><!-- end item c8ee52fb-239a-45f4-a905-a70700ff22c5 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}